Products of cyclooxygenase-2 depress duodenal function in rats subjected to abdominal surgery

L Pihl1, O Nylander

  • 1Department of Neuroscience, Division of Physiology, Biomedical Center, Uppsala University, Uppsala, Sweden.

Abstract

Insights

Cyclooxygenase-2 (COX-2) inhibition improves post-operative duodenal function by enhancing motility and bicarbonate secretion. This suggests COX-2 plays a key role in post-abdominal surgery ileus.

Area of Science:

  • Gastroenterology
  • Surgical Physiology
  • Pharmacology

Background:

  • Abdominal surgery significantly impacts gastrointestinal functions, including duodenal motility and secretion.
  • Post-operative ileus is a common complication affecting recovery after abdominal procedures.
  • The roles of cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) in post-operative duodenal dysfunction remain to be fully elucidated.

Purpose of the Study:

  • To investigate the specific roles of COX-1 and COX-2 isoforms in the development of post-operative duodenal ileus.
  • To determine the effects of selective COX-1 and COX-2 inhibition on duodenal function following surgical stress.

Main Methods:

  • In situ perfusion of rat proximal duodenum with isotonic or hypotonic NaCl.
  • Measurement of mucosal bicarbonate secretion, motility, mucosal permeability, and effluent osmolality.
  • Assessment of these parameters in the absence and presence of selective COX-1 and COX-2 inhibitors (SC-560, rofecoxib, parecoxib).

Main Results:

  • Selective COX-2 inhibition (rofecoxib, parecoxib) significantly increased duodenal motility, bicarbonate secretion, and mucosal permeability response to hypotonicity.
  • COX-2 inhibition enhanced the duodenum's capacity to adjust luminal osmolality.
  • Selective COX-1 inhibition (SC-560) showed only transient effects on motility and secretion, with a less pronounced impact on mucosal permeability compared to COX-2 inhibition.

Conclusions:

  • Abdominal surgery elevates prostanoid synthesis, primarily via COX-2, impairing duodenal contractility, bicarbonate secretion, and osmolality regulation.
  • COX-2 inhibition ameliorates post-operative duodenal ileus by restoring these functions.
  • Pre-treatment with COX-2 inhibitors should be considered in studies of gastrointestinal function following abdominal surgery.

Related Concept Videos

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents01:20

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Peptic Ulcer Disease II: Pathophysiology01:24

Peptic Ulcer Disease II: Pathophysiology

Peptic ulcer disease develops when protective mechanisms of the gastrointestinal mucosa are overwhelmed by harmful factors, leading to localized erosions in the stomach or proximal duodenum. The main causes are Helicobacter pylori infection and chronic use of nonsteroidal anti-inflammatory drugs (NSAIDs).Helicobacter pylori–Induced InjuryBacterial Adaptation and Colonization:H. pylori is a spiral, Gram-negative bacterium adapted to the acidic stomach. and transmitted through oral-oral or...
Gastritis-II: Pathophysiology01:17

Gastritis-II: Pathophysiology

Gastritis is marked by disruption of the mucosal barrier that usually protects the stomach tissue from digestive juices and manifests in acute and chronic forms.
In acute gastritis, the gastric mucosa becomes swollen and red and undergoes superficial erosion. Superficial ulceration may lead to bleeding.
In chronic gastritis, persistent or repeated insults lead to chronic inflammatory changes and, eventually, thinning or atrophy of the gastric tissue.
Gastritis can stem from various causes, each...
Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors01:24

Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors

Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI)  tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining. Bicarbonate,...
Peptic Ulcer Disease I: Introduction01:30

Peptic Ulcer Disease I: Introduction

Peptic Ulcer Disease (PUD) is characterized by mucosal excavation in the esophagus, stomach, pylorus, or duodenum. It can manifest as acute or chronic based on the extent and duration of mucosal involvement.
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
Pathophysiology of Peptic Ulcer Disease: Injurious Factors01:22

Pathophysiology of Peptic Ulcer Disease: Injurious Factors

Peptic ulcers are sores on the stomach's inner lining and the upper small intestine, which are the result of disruptions in the mucosal layer that houses parietal cells which produce gastric acid, and chief cells which secrete pepsinogen.
In the antrum region, G cells secrete the gastrin hormone that binds to gastrin-cholecystokinin-B (CCK2) receptors on parietal and enterochromaffin-like (ECL) cells in the fundic glands. Simultaneously, the vagus nerve releases acetylcholine, which binds to M3...